Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Monoethanolamine SCHEMBL7053890 | 0.79 | KMT2A (0.58) | KMT2AMEN1F2PRSS1PRSS2 | |
| SCHEMBL1682781 | 0.79 | TDP1 (0.44) | HPGDKMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL63933 | 0.78 | KMT2A (0.70) | HPGDKMT2AMEN1F2PRSS1 | |
| SCHEMBL151052 | 0.78 | KMT2A (0.70) | HPGDKMT2AMEN1F2PRSS1 | |
| SCHEMBL9754556 | 0.78 | KMT2A (0.70) | HPGDKMT2AMEN1F2PRSS1 | |
| SCHEMBL1989355 | 0.78 | KMT2A (0.46) | HTTHPGDKMT2AMEN1F2 | |
| Nitric Acid SCHEMBL9875748 | 0.77 | TAAR1 (0.47) | HTTHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL4580867 | 0.77 | KMT2A (0.68) | HPGDKMT2AMEN1F2PRSS1 | |
| SCHEMBL3749170 | 0.77 | KMT2A (0.68) | HPGDKMT2AMEN1F2PRSS1 | |
| Fluoride SCHEMBL11758885 | 0.77 | KMT2A (0.68) | HPGDKMT2AMEN1F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305877-A1 | Processes for the Preparation of Rotigotine and Intermediates Thereof | APOTEX INC. (CA) | 2017-10-26 | — | — | US | disclosed |
| US-9499526-B2 | Compositions and methods for the treatment of neurologic diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-20160297745-A1 | ENDODONTIC POST SYSTEM | APOTEX INC (CA) | 2016-10-13 | — | — | US | disclosed |
| WO-2016044918-A1 | PROCESSES FOR THE PREPARATION OF ROTIGOTINE AND INTERMEDIATES THEREOF | APOTEX INC. (CA) | 2016-03-31 | — | — | WO | disclosed |
| US-20150218136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGIC DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2015-08-06 | — | — | US | disclosed |
| US-8604242-B2 | Process for the preparation of optically active (S)-(−)-2-(N-propylamino)-5-methoxytetraline and (S)-(−)-2-(N-propylamino)-5-hydroxytetraline compounds | INTERQUIM, S.A. (ES) | 2013-12-10 | — | — | US | disclosed |
| US-8513438-B2 | Process for the preparation of (6S)-(-)-5,6,7,8-tetrahydro-6-[propyl-(2-thienyl)ethyl]amino-1-naphthol (Rotigotine) | INTERQUIM, S.A. (ES) | 2013-08-20 | — | — | US | disclosed |
| US-8513438-B2 | Process for the preparation of (6S)-(-)-5,6,7,8-tetrahydro-6-[propyl-(2-thienyl)ethyl]amino-1-naphthol (Rotigotine) | INTERQUIM, S.A. (ES) | 2013-08-20 | — | — | US | disclosed |
| EP-2376470-B1 | PROCESS FOR THE PREPARATION OF (6S)-(-)-5,6,7,8-TETRAHYDRO-6-[PROPYL-(2-THIENYL)ETHYL]AMINO-1-NAPHTHOL (ROTIGOTINE) | INTERQUIM SA (ES) | 2013-04-10 | — | — | EP | disclosed |
| EP-2346811-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE (S)-(-)-2-(N-PROPYLAMINO)-5-METHOXYTETRALINE AND (S)-(-)-2-(N-PROPYLAMINO)-5-HYDROXYTETRALINE COMPOUNDS | INTERQUIM SA (ES) | 2012-08-15 | — | — | EP | disclosed |
| US-20110306776-A1 | PROCESS FOR THE PREPARATION OF (6S)-(-)-5,6,7,8-TETRAHYDRO-6-[PROPYL-(2-THIENYL)ETHYL]AMINO-1-NAPHTHOL (ROTIGOTINE) | INTERQUIM, S.A. (ES) | 2011-12-15 | — | — | US | disclosed |
| EP-2376470-A1 | PROCESS FOR THE PREPARATION OF (6S)-(-)-5,6,7,8-TETRAHYDRO-6-ÝPROPYL-(2-THIENYL)ETHYL¨AMINO-1-NAPHTHOL (ROTIGOTINE) | Interquim, S.A (ES) | 2011-10-19 | — | — | EP | disclosed |
| EP-2376470-A1 | PROCESS FOR THE PREPARATION OF (6S)-(-)-5,6,7,8-TETRAHYDRO-6-ÝPROPYL-(2-THIENYL)ETHYL¨AMINO-1-NAPHTHOL (ROTIGOTINE) | Interquim, S.A (ES) | 2011-10-19 | — | — | EP | disclosed |
| EP-2346811-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE (S)-(-)-2-(N-PROPYLAMINO)-5-METHOXYTETRALINE AND (S)-(-)-2-(N-PROPYLAMINO)-5-HYDROXYTETRALINE COMPOUNDS | Interquim, S.A (ES) | 2011-07-27 | — | — | EP | disclosed |
| US-20110152543-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE (S)-(-)-2-(N-PROPYLAMINO)-5-METHOXYTETRALINE AND (S)-(-)-2-(N-PROPYLAMINO)-5-HYDROXYTETRALINE COMPOUNDS | INTERQUIM, S.A. (ES) | 2011-06-23 | — | — | US | disclosed |
| WO-2010066755-A1 | PROCESS FOR THE PREPARATION OF (6S)-(-)-5,6,7,8-TETRAHYDRO-6-[PROPYL-(2-THIENYL)ETHYL]AMINO-1-NAPHTHOL (ROTIGOTINE) | INTERQUIM, S.A. (ES) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010066755-A1 | PROCESS FOR THE PREPARATION OF (6S)-(-)-5,6,7,8-TETRAHYDRO-6-[PROPYL-(2-THIENYL)ETHYL]AMINO-1-NAPHTHOL (ROTIGOTINE) | INTERQUIM, S.A. (ES) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010043571-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE (S)-(-)-2-(N-PROPYLAMINO)-5-METHOXYTETRALINE AND (S)-(-)-2-(N-PROPYLAMINO)-5-HYDROXYTETRALINE COMPOUNDS | INTERQUIM, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGIC DISEASES | PYGB, PSEN1, SI | HTT 9/4885HPGD 1780/4885KMT2A 3418/4885 |
| US-20110306776-A1 | PROCESS FOR THE PREPARATION OF (6S)-(-)-5,6,7,8-TETRAHYDRO-6-[PROPYL-(2-THIENYL)ETHYL]AMINO-1-NAPHTHOL (ROTIGOTINE) | NAT1, COMT, PARK7 | HTT 107/4885HPGD 299/4885KMT2A 2747/4885 |
| US-20170305877-A1 | Processes for the Preparation of Rotigotine and Intermediates Thereof | C1S, C1R, C3AR1 | HTT 1626/4885HPGD 2487/4885KMT2A 2130/4885 |
| US-20160297745-A1 | ENDODONTIC POST SYSTEM | ABCB11, EXOC3, C1S | HTT 3801/4885HPGD 3874/4885KMT2A 3832/4885 |
| US-20110152543-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE (S)-(-)-2-(N-PROPYLAMINO)-5-METHOXYTETRALINE AND (S)-(-)-2-(N-PROPYLAMINO)-5-HYDROXYTETRALINE COMPOUNDS | PARK7, THOP1, SNCA | HTT 10/4885HPGD 552/4885KMT2A 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.